Plunkett Research Online: Rigel Pharmaceuticals Inc

RIGEL PHARMACEUTICALS INC (RIGL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Ri.....



Rigel Pharmaceuticals Inc
Ticker: RIGL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 624-1100
Fax: 650 624-1101
Address: 611 Gateway Boulevard
Suite 900
South San Francisco, CA 94080 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biopharmaceuticals Development
Biotechnology
Small Molecule Drugs
Drug Development
Drug Production
Clinical Testing
Drug Commercialization
Contacts Description
Raul RodriguezCEO/Director/President
Dean SchornoCFO/Executive VP
See More
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Ri.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202220212020201920182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
TAVALISSE
R835
R552
Rxxx
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: